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Abstract
Aim: We aimed to determine the prevalence of and factors associated with maternal 
use of nicotine products in relation to breastfeeding.
Methods: Nicotine use 3 months postpartum was determined in the Scandinavian 
PreventADALL mother-child birth cohort study recruiting 1837 women from 2014 
to 2016. Electronic questionnaires at 18 weeks pregnancy and 3 months postpartum 
provided information on snus use, smoking or other nicotine use, infant feeding and 
socio-economic factors. The risk of nicotine use in relation to breastfeeding was ana-
lysed with logistic regression.
Results: Overall, 5.6% of women used snus (2.9%), smoked (2.7%) or both (n = 2) 
3 months postpartum, while one used other nicotine products. Among the 1717 
breastfeeding women, 95.1% reported no nicotine use, while 2.4% used snus, 2.5% 
smoked and one dual user. Compared to 3.7% nicotine use in exclusively breastfeeding 
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1  | INTRODUC TION
Exposure to cigarette smoking and other nicotine products in early 
life, including preconceptional period and during pregnancy, may 
cause adverse health outcomes in the infant.1-3 Moreover, breastfed 
infants exposed to smoking or snus by their nursing mothers are ex-
posed to high levels of nicotine through the breast milk.4,5 Nicotine 
may remain in the breast milk for 12.5 hours after the last snus dose 
and 4 hours after the last cigarette.5 Smoking during breastfeeding 
has been shown to reduce the health promoting properties of breast 
milk including lower fat concentration, reduced milk production 
possibly through reduced levels of prolactin, shorter breastfeed-
ing periods6 and may affect the taste of the breast milk. Moreover, 
an increased risk for several conditions has been observed in the 
smoke-exposed infant, including colic, sleep disruption,7 allergies, 
respiratory disorders,6,8 neurobehavioural disorders,7 sudden infant 
death syndrome,6,7 altered heart rate variability,9 and overweight 
and obesity later in life.7
In contrast to smoking during and after pregnancy, information 
on the use of snus and other nicotine products in relation to breast-
feeding is largely lacking.2 In a study conducted in 2009 in Italy, 8.1% 
of around 3700 women reported smoking 3 months postpartum, 
with a prevalence of 5.2% among breastfeeding women.10 Further, 
12 months postpartum, the corresponding rates were 10.9% and 
6.6%, respectively.10 Recent Swedish statistics reported maternal 
smoking among 3% one month postpartum and 4% eight months 
postpartum.11 We are unaware of data related to the use of snus or 
nicotine replacement therapies (NRT) during breastfeeding.
Risk factors for postpartum smoking include smoking or expo-
sure to second-hand smoking prior to, or during pregnancy, lower 
education, younger age, multiparity, stress, depression or anxiety, 
and not breastfeeding.12,13 Risk factors for snus or NRT use postpar-
tum are not known. A Swedish register study recently reported that 
1.1% of women used snus in early pregnancy.14 Among the women 
recruited to the Preventing Atopic Dermatitis and ALLergies study 
(PreventADALL), 0.6% reported snus use at approximately 18 weeks 
and 0.3% at 34 weeks of pregnancy.15 Although 11.3% reported use 
of any nicotine-containing product of whom 6.5% used snus and 4.1% 
reported smoking in the first 34 weeks of pregnancy, most women 
stopped using nicotine-containing products when they recognised 
their pregnancy.15 The breastfeeding rates in Scandinavia are high, 
with 84%-86% reporting exclusively or partly breastfeeding in the 
first 2-3 months postpartum in Norway16 and Sweden.11 Despite re-
duced female smoking rates in the recent decades, the breastfeed-
ing infant is faced with an unknown threat due to increased nicotine 
use seen as snus use in the Scandinavian countries and as electronic 
cigarettes (e-cigarettes) in the USA.17
The primary aim of the present study was therefore to determine 
the prevalence of maternal smoking and use of nicotine products 
during breastfeeding. The secondary aim was to determine whether 
nicotine use differed among exclusively, partly or non-breastfeeding 
women, and to identify factors associated with use of nicotine prod-
ucts 3 months postpartum.
2  | SUBJEC TS AND METHODS
2.1 | Study design
The present study used data from the Scandinavian, PreventADALL 
study, a prospective general population-based mother-child cohort 
established in December 2014, investigating the effects of primary 
prevention strategies for reducing allergic diseases, as well as as-
sessing early life factors involved in development of allergic and 
other non-communicable diseases.
Council—the Initiative for Clinical Therapy 
Research, The Swedish Heart—Lung 
Foundation, SFO-V Karolinska Institutet, 
Hesselman Research Foundation.
women (n = 1242), the risk of nicotine use increased by partly (OR 2.26, 95% CI 1.45-
3.52) and no breastfeeding (OR 4.58, 95% CI 2.57-8.21). Nicotine use before (14.5% 
snus, 16.4% smoking) or in pregnancy (0.2% snus, 0.4% smoking) significantly in-
creased the risk of using nicotine during breastfeeding.
Conclusion: Few breastfeeding women used snus or smoked 3 months postpartum, 
with increased risk by nicotine use before or during pregnancy.
K E Y W O R D S
birth cohort, breastfeeding, maternal smoking, pregnancy, snus use
Key notes
• The use of various nicotine products during breastfeed-
ing is not well known.
• Among breastfeeding women 3 months postpartum, 
95% did not use nicotine products, the lowest rates of 
snus use (1.9%) or smoking (1.9%) were observed in ex-
clusively breastfeeding women and the risk of nicotine 
use during breastfeeding increased by nicotine use be-
fore and in pregnancy.
• Young women should be discouraged from ever using 
nicotine products.
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All pregnant women scheduled for routine 18-week gestational age 
(GA) ultrasound screening at hospitals in Oslo and Østfold (Norway) 
and Stockholm, Sweden, were invited to participate in the study. 
Overall, 2697 women with 2701 pregnancies were enrolled within 
22 months, 2149 in Norway and 552 in Sweden.18 Inclusion criteria 
were singleton or twin pregnancies at 16-22 gestational weeks and 
sufficient Scandinavian language skills. Exclusion criteria were severe 
maternal or foetal disease, or plans to move from the area within the 
first year of the child's life. Their healthy infants born at GA of at least 
35.0 weeks were enrolled at birth, totalling 2397 mother-child pairs.18
The enrolment visit in connection with the ultrasound screen-
ing included signing the written informed consent, a brief interview, 
as well as height, weight and blood pressure measurement. Shortly 
after enrolment, women completed an extensive electronic ques-
tionnaire including socio-economic, demographic, lifestyle and med-
ical history data.
The infants were included at the maternity ward after obtain-
ing signed informed consent by both parents, whenever possible. 
Obstetric history and birth outcomes were retrieved from electronic 
hospital charts by dedicated study personnel. The infants attended 
follow-up visits at 3, 6 and 12 months of age, including clinical in-
vestigations and biological sampling. Electronic questionnaires with 
information of health and disease in the mother, child and the family, 
lifestyle, environment, stress, diet and maternal use of nicotine prod-
ucts were completed by the mother at the infant age of 3 months, 
with further follow-up studies not reported in the present study.18
2.2 | Subjects
The present study included all 1837 women who completed the 
18 weeks pregnancy questionnaire as well as the 3 months post-
partum questionnaire (Figure 1). With the exception of a smaller 
proportion having low income, lower educational attainment level, 
younger age, several previous pregnancies, use of snus and smoking 
prior to pregnancy, the included women were largely similar to the 
863 women who were not included in the present study (Table S1).
2.3 | Methods
Electronic questionnaires were developed in collaboration with the 
University Center for Information Technology of the University 
of Oslo18 and sent by e-mail to the participating women at 18 and 
F I G U R E  1   Flow chart of the 
PreventADALL study and number of 
women who completed the 18 wks 
pregnancy questionnaire and 3 mo 
postpartum questionnaire
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34 weeks of pregnancy and at 3 months postpartum. The 18 weeks 
pregnancy questionnaire included data on demographic character-
istics, medical history and lifestyle. All questionnaires focused on 
maternal smoking, use of snus and other nicotine products includ-
ing, but not limited to e-cigarettes, NRT, cigar/cigarillo or pipe, be-
fore and during pregnancy. The 3 months postpartum questionnaire 
also included detailed information on infant feeding, proportion of 
breastfeeding, bottle feeding, use of infant formula or other food.
Smoking or use of nicotine products was recorded in relation to 
the time up to enrolment in the 18 weeks pregnancy questionnaire, 
from enrolment to presently in the 34 weeks pregnancy question-
naire from 34 weeks to delivery as well as for the last 3 months in 
the 3 months postpartum questionnaire. The women were asked 
whether they had smoked or used any nicotine products ever in the 
18 weeks pregnancy questionnaire. If yes, they responded to the fol-
lowing mutually excluding categories; for smoking, snus use or other 
nicotine use; I stopped several years ago, I stopped just before the 
pregnancy, I stopped when recognising pregnancy, I have smoked/
used snus or other nicotine products during the pregnancy. In the 
3 months postpartum questionnaire, the women reported any use 
of nicotine products with the following options; no, yes or do not 
know, followed by further questions if answering yes; in which they 
recorded daily or occasional smoking or use of snus. The following 
mutually exclusive categories were used; less than once per month, 
less than weekly, approximately 1-2 days per week, approximately 
3-5 days per week or daily. Further, they recorded the number of 
cigarettes or snus doses per day and per month.15 For other nicotine 
products, the categories were as follows: never, less than monthly, 
1-3 times per month, once weekly, 1-5 times per day, 6-10 times or 
>10 times per day.
Use of smoking and nicotine product is reported in terms of 
smoking, snus use, dual users (smoking and snus use), e-cigarettes, 
NRT (patches or gum/lozenges/spray) and other nicotine products 
(cigar/cigarillo, pipe, other).
The PreventADALL study was approved by the Regional 
Committee for Medical and Health Research Ethics in South-Eastern 
Norway (2014/518) and in Sweden (2014/2242-31/4) as well as reg-
istered at clinicaltrials.gov (number NCT02449850).
2.4 | Outcomes, definitions and 
explanatory variables
The main outcome was maternal smoking and/or use of other nic-
otine products, defined as daily or occasional use during the first 
three postpartum months.
Possible explanatory variables for smoking or use of nicotine 
products during breastfeeding included maternal age by three cat-
egories: 16-24, 25-34, >35 years. Maternal and paternal education 
level were reported by three categories as primary or high school 
only, higher education of <4 years and higher education of more than 
4 years. Marital status was categorised into married, cohabitant, and 
single or separated or other. Country of origin was given as Norway, 
Sweden, other Nordic and other countries. Total household income 
was classified as low, middle and high based upon conversion into 
<30 000, 30 000-100 000 and >100 000 Euros, respectively. Living 
environment was categorised into densely populated city, city less 
densely populated, suburb, village or countryside outside village. 
The number of previous pregnancies was given as none, one or more 
than one. Maternal smoking and snus use were classified as use be-
fore pregnancy and use during pregnancy.
2.5 | Statistical analysis
Categorical variables are presented as number and percentages, and 
continuous variables as means and minimum-maximum. Possible 
differences between categorical variables were analysed with the 
chi-square test. Associations between the use of nicotine products 
postpartum and breastfeeding, as well as for exploration of factors 
associated with use of nicotine during breastfeeding, were estimated 
using multiple logistic regression analyses. The results are expressed 
as odds ratios (OR) with 95% confidence intervals (CI). Significance 
level was set to 0.05. All tests were two-sided. Since all analyses 
were exploratory, no correction for multiple testing was made. All 
analyses were performed by SPSS statistics version 25 (IBM).
3  | RESULTS
The baseline characteristics of the participating women at 18 weeks 
of pregnancy are given in Table S1. The mean age at enrolment was 
32.5 years, and the majority of women were born in Norway or 
Sweden.
The vast majority of women breastfed their infant at 3 months 
of age, with 1242 (67.7%) exclusively and 475 (25.9%) partly breast-
feeding, while 120 (6.5%) women did not breastfeed (Table 1).
Use of nicotine prior to and/or during pregnancy is outlined in 
Table S1. Briefly, snus use was reported by 14.5% before pregnancy, 
while the majority stopped at the time of recognising the pregnancy. 
Only 0.2% used snus at approximately 18 week pregnancy. The cor-
responding figures for smoking were 16.4% before pregnancy and 
0.4% in mid-pregnancy.
At 3 months postpartum, the majority of mothers (94.4%) did not 
report use of any nicotine product, while 102 (5.6%) reported use of 
any nicotine products; 50 (2.7%) reporting smoking, 54 (2.9%) re-
porting snus use and two were dual users. One breastfeeding woman 
reported use of other non-specified nicotine products (Table 2).
Among all 1717 breastfeeding women, 84 (4.9%) reported use 
of snus or smoking 3 months postpartum, with 2.4% reporting 
smoking, 2.5% used snus, and one was a dual user. Most women re-
ported occasional smoking or snus use, with daily snus use in 0.9% 
of women and daily smoking in 0.4% (Table S2). The use of snus 
and smoking was similar in Norway and Sweden (Table S3). None 
of the breastfeeding women reported use of NRT or e-cigarettes, 
while one woman reported use of other non-specified nicotine 
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Median maternal age–year(min-max)  32.5 (21-45) 32.7 (20-48) 32 (21-43)
Age, mother*-n (%) 1837    
16-24 y  18 (1.4) 10 (2.1) 7 (5.8)
25-34 y  869 (70.0) 308 (64.8) 77 (64.2)
35-44 y  353 (28.4) 155 (32.6) 36 (30.0)
>45 y  2 (0.2) 2 (0.4) 0 (0.0)
Education mother*-n (%) 1700    
Primary school  4 (0.3) 1 (0.2) 5 (4.6)
High school  82 (7.1) 51 (11.6) 28 (25.7)
Higher education < 4 y  348 (30.3) 132 (29.9) 40 (36.7)
Higher education > 4 y  716 (62.3) 257 (58.3) 36 (33.0)
Education partner*-n (%) 1632    
Primary school  11 (1.0) 5 (1.2) 3 (2.9)
High school  178 (16.1) 85 (20.0) 36 (35.0)
Higher education < 4 y  323 (29.3) 133 (31.3) 32 (31.1)
Higher education > 4 y  592 (53.6) 202 (47.5) 32 (31.1)
Marital status*-n (%) 1709    
Married  498 (43.0) 178 (40.4) 36 (41.7)
Cohabitant  639 (55.2) 252 (57.1) 68 (61.3)
Single  12 (1.0) 10 (2.3) 4 (3.6)
Other  8 (0.7) 1 (0.2) 3 (2.7)
Country of origin*-n (%) 1709    
Norway  803 (69.4) 272 (61.7) 68 (61.3)
Sweden  237 (20.5) 125 (28.3) 25 (22.5)
Other Nordic  17 (1.5) 3 (0.7) 1 (0.9)
Other  100 (8.6) 41 (9.3) 17 (15.3)
Family income*-n (%) 1686    
Low  5 (0.4) 4 (0.9) 4 (3.8)
Middle  594 (51.8) 254 (58.7) 66 (62.3)
High  548 (47.8) 175 (40.4) 36 (34.0)
Living environment*-n (%) 1709    
City, densely populated  458 (39.6) 186 (42.2) 31 (27.9)
City, less dense populated  448 (38.7) 146 (33.1) 49 (44.1)
Suburb  168 (14.5) 85 (19.3) 18 (16.2)
Countryside, in village  28 (2.4) 7 (1.6) 1 (0.9)
Countryside, outside village  55 (4.8) 17 (3.9) 12 (10.8)
Previous pregnancy-n (%) 1837    
0  597 (48.1) 259 (54.5) 69 (52.5)
1  334 (26.9) 113 (23.8) 23 (19.2)
>1  311 (25.0) 103 (21.7) 34 (28.3)
Snus use-n (%) 1837    
No  982 (79.1) 369 (77.7) 98 (81.7)
Use before pregnancy  183 (14.7) 71 (14.9) 12 (10.0)
Stop when recognised pregnancy  73 (5.9) 35 (7.4) 10 (8.3)
(Continues)
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products (Table 2). Women who did not breastfeed 3 months post-
partum used snus or smoking significantly more often than women 
who were partly or exclusively breastfeeding (Table 2). Compared 
with exclusively breastfeeding women, partly breastfeeding 
women had 2.3 times higher odds for using snus or smoking (OR 
2.26, 95% CI 1.45-3.52) while the odds were 4.6 times higher in 
non-breastfeeding women (OR 4.58, 95% CI 2.57-8.21), shown as 
estimated proportions (with 95% CI) (Figure 2).
In univariate logistic regression analyses, the following charac-
teristics were all significantly associated with maternal smoking and 
use of snus during breastfeeding at 3 months postpartum: maternal 








Use in pregnancy  4 (0.3) 0 (0.0) 0 (0.0)
Use before pregnancy and relapse  5 (0.4) 5 (1.1) 1 (0.8)
Stop when recognised pregnancy 
and relapse
 13 (1.0) 14 (2.9) 8 (6.7)
Use in pregnancy and persistent 
use postpartum
 3 (0.2) 0 (0.0) 0 (0.0)
No use before pregnancy but use 
postpartum
 2 (0.2) 1 (0.2) 2 (1.7)
Use daily postpartum  8 (0.6) 2 (0.4) 6 (5.0)
Use occasionally postpartum  15 (1.2) 18 (3.8) 5 (4.2)
Smoking *-n (%)  1837    
No 1001 (80.6) 364 (76.6) 99 (82.5)
Use before pregnancy  203 (16.3) 83 (17.5) 15 (12.5)
Stop when recognised pregnancy  34 (2.7) 27 (5.7) 4 (3.3)
Use in pregnancy  4 (0.3) 1 (0.2) 2 (1.7)
Use before pregnancy and relapse  5 (0.4) 4 (0.8) 1 (0.8)
Stop when recognised pregnancy 
and relapse
 7 (0.6) 9 (1.9) 2 (1.7)
Use in pregnancy and persistent 
use postpartum
 4 (0.3) 1 (0.2) 2 (1.7)
No use before pregnancy but use 
postpartum
 7 (0.6) 5 (1.0) 3 (2.5)
Use daily postpartum  3 (0.2) 1 (0.2) 3 (2.5)
Use occasionally postpartum  20 (1.6) 18 (3.8) 5 (4.2)
Note: Data are presented as median (min-max) or n (%), No. =number
*P-value < .05. Postpartum = is the time from birth to 3 mo. 














No use—n (%) 1196 (96.3) 437 (92.0) 102 (85.0) 1735 (94.4)
Any use 46 (3.7) 38 (8.0) 18 (15.0) 102 (5.6)
Snus 23 (1.9) 20 (4.2) 11 (9.2)
Cigarette 23 (1.9) 19 (4.0) 8 (6.7)  
Dual users 0 1 (0.2) 1 (0.8)  
E-cigarette 0 0 0  




1 (0.1) 0  0  
Note: P-value < .05 in bold.
TA B L E  2   Use of nicotine-containing 
products at 3 mo postpartum according to 
breastfeeding group
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and/or use of snus before and during pregnancy. In multiple regres-
sion analyses adjusted for the significant explanatory variables, snus 
use before pregnancy, smoking and/or snus use during pregnancy 
and middle compared with high family income were most strongly 
association with use of snus or smoking during breastfeeding, as 
shown in Table 3.
4  | DISCUSSION
In this Scandinavian mother-child cohort with a 94% breastfeed-
ing rate 3 months postpartum, 4.9% of the breastfeeding women 
reported use of snus or smoking, with 2.4% of women reporting 
smoking and 2.5% snus use. The lowest prevalence was 3.7% among 
exclusively breastfeeding women, with 8.0% of partly breastfeed-
ing and 15.0% of non-breastfeeding women reporting use of snus 
or smoking 3 months postpartum. None reported use of NRT or 
e-cigarette. Use of snus before pregnancy, maternal smoking and/
or use of snus during pregnancy and middle family income signifi-
cantly increased the risk of maternal smoking and snus use during 
breastfeeding.
The prevalence of snus use 3 months postpartum is to our knowl-
edge novel. However, our observed 3% smoking rate, similar to snus 
use, is in line with the reported smoking rates of 3% one month post-
partum and 4% eight months postpartum in a recent Swedish na-
tionwide survey.11 The low rate of nicotine use in the PreventADALL 
cohort of well-educated mothers, compared with the 13% postpar-
tum smoking rate reported from the USA two decades ago,19 is likely 
to reflect the changing patterns over time of nicotine use among 
women of child bearing age.1 In particular, our observation that snus 
use was at least as common as smoking during breastfeeding is in 
line with the observed increase in snus use and decreasing smoking 
rates over the recent years among young women in Scandinavia.20,21
The rates of snus use in exclusively breastfeeding women of 2% 
compared to 4% in partly breastfeeding and 9% in non-breastfeed-
ing women are to the best of our knowledge the first documentation 
of use of nicotine products other than smoking during breastfeed-
ing. Our results are supported by studies showing that breastfeeding 
duration was shorter among smokers compared with non-smok-
ers.19,22,23 Moreover, with the nicotine content in snus being at 
least as high as in cigarettes,4,5 some adverse effects may be similar 
for snus use and smoking, including reduced milk production and 
shorter breastfeeding periods.6 The rate of daily snus use or smok-
ing 3 months postpartum was <1% in our study, and the observed 
breastfeeding rate of 93.5% is somewhat higher than the average 
breastfeeding rate of 86% at 3 months from Norwegian 16 and 84% 
at 2 months from Swedish general statistics.11 This high rate may 
indicate a population selection in favour of well-educated urban 
women in the PreventADALL study.
Another novelty in our study was the observation that nicotine 
use other than smoking during breastfeeding was significantly asso-
ciated with maternal smoking or use of snus in pregnancy. Our find-
ings are supported by a recent meta-analysis including 31 studies 
showing that maternal smoking at the start of pregnancy, regardless 
of temporary quitting in pregnancy, predicted relapse to smok-
ing postpartum.12 The observed higher rate of nicotine use among 
non-breastfeeding women is in line with other studies showing a 
clearly increased risk of postpartum smoking relapse in women not 
breastfeeding.6,12,13,24 Lower family income was associated with ma-
ternal smoking and snus use during breastfeeding in the univariate 
regression analysis, which is in line with a report from the Norwegian 
Institute of Public Health.25 However, only middle socio-economic 
status was significantly associated with nicotine use in breastfeeding 
women in the final multivariate model. The low rates of nicotine use 
in our study limit the statistical study power, reducing our ability to 
identify significant risk factors for nicotine use during breastfeeding. 
However, socio-economic factors are inconsistent as predictors for 
relapse of smoking after childbirth.12,26 Although maternal smoking 
before pregnancy was not significantly associated with smoking 
during breastfeeding in our study, the magnitude of the estimate sup-
ports an association and a lack of statistical power may explain the 
borderline significance level. Other studies report an association of 
F I G U R E  2   Maternal use of nicotine products in relation to breastfeeding
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TA B L E  3   The odds for the use of any nicotine-containing product during breastfeeding at 3 mo postpartum
 n Univariate analyses (OR,95% CI) Multivariate analyses (OR, 95% CI)
Age mother 1837   
16-24 y  (3.23,1.04-10.01) (0.42, 0.03-5.29)
25-34 y  (1.64, 1.00-2.68) (1.11, 0.56-2.19)
>35 y (ref)  1  
Education mother 1700   
Primary/high school  (3.48, 1.96-6.15) (1.10, 0.42-2.86)
Higher education < 4 y  (1.89, 1.17-3.04) (0.96, 0.51-1.81)
Higher education > 4 y (ref)  1  
Education partner 1632   
Primary/high school  (4.23, 2.42-7.37) (1.56, 0.69-3.55)
Higher education < 4 y  (2.65, 1.52-4.60) (1.75, 0.90-3.40)
Higher education > 4 y (ref)  1  
Marital status 1709   
Married (ref)  1  
Cohabitant  (1.18, 0.73-1.91)  
Single/separated/other  (1.53, 0.35-6.76)  
Country of origin 1709   
Norway (ref)  1  
Sweden/other Nordic  (0.97, 0.58-1.63)  
Other  (1.35, 0.69-2.62)  
Family incomes 1686   
Low  (17.31, 4.89-61.19) (7.02, 0.93-52.85)
Middle  (3.13, 1.86-5.25) (1.92,1.01-3.64)
High (ref)  1  
Living environment 1709   
City, densely populated (ref)  1  
City, less dense populated  (0.88, 0.54-1.42)  
Suburb  (0.82, 0.43-1.56)  
Village  (0.95, 0.22-4.14)  
Countryside, outside village  (1.03, 0.39-2.69)  
Previous pregnancies 1837   
0 (ref)  1  
1  (0.56, 0.30-1.06)  
>1  (1.37, 0.84-2.24)  
Snus use 1837   
No  1  
Use before pregnancy  (2.32, 1.28-4.23) (2.64, 1.24-5.61)
Use in pregnancy  (12.64, 7.46 - 21.44) (16.15, 7.92-32.95)
Smoking 1837   
No  1  
Use before pregnancy  (3.38, 1.98-5.76) (1.84, 0.95-3.57)
Use in pregnancy  (21.10, 11.57-38.47) (31.54, 15.02-66.21)
Note: P-value < .05 in bold. Results are shown by univariate and multivariate analyses, adjusting for factors that were significantly associated with the 
outcome in the univariate analyses.
Abbreviation: CI, confidence interval; OR, Odds ratio.
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maternal smoking before pregnancy and relapse postpartum.12,13,27 
The inconsistency with other studies may be related to our limited 
study period of 3 months postpartum, as relapsing to postpartum 
smoking tends to increase over time from delivery.13,22,27
Generalisability of our results may be limited by several fac-
tors. The enrolled women in the PreventADALL study generally 
had a higher educational level than the respective national aver-
age,18 which may affect smoking levels found to be higher among 
women with a lower educational level.25 Moreover, the majority of 
the women lived in cities, in line with the observed high median in-
comes observed in metropolitan areas.21 However, average maternal 
age in the PreventADALL study was comparable to the average age 
at delivery in Norway and Sweden.11,20 The lack of reported use of 
nicotine-containing e-cigarettes in our study is probably because 
these have not been legally sold in Norway and Sweden during 
the study period, whereas snus on the other hand, being common 
in Sweden and increasingly used in Norway, is uncommon or illegal 
in most countries outside Scandinavia. Our study likely reflects na-
tional changes in use of tobacco products over time, with decreas-
ing smoking rates, but increasing use of snus among women in the 
childbearing age.20
The lack of information about partner's nicotine use in this study 
may have had an impact on our results as women who have a partner 
who smokes are at greater risk of smoking relapse postpartum.24
Another potential limitation of our study is that data are 
based on self-reports with no objective validation of nicotine or 
cotinine levels in breast milk or infant sera. Studies have how-
ever shown that self-reports represent valid markers for tobacco 
exposure.28,29
5  | CONCLUSION
At 3 months postpartum, 5.6% of all women in our Scandinavian 
mother-child birth cohort study used any nicotine product with 
similar snus and smoking rates. None reported use of e-cigarettes 
or NRT, and one used a non-specified product. Among breastfeed-
ing women, 95.1% did not use any nicotine products, snus and 
smoking rates were similar at 2.4 and 2.5% and exclusively breast-
feeding mothers were least likely to use nicotine. Use of nicotine 
before and during pregnancy increased the risk of using snus or 
smoking during breastfeeding highlighting the need to target strat-
egies to young women to prevent them from ever using nicotine 
products.
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